ArticleMaterials today. Bio2025
A nano-immuno-cruise delivery system encapsulated lipid-integrated bilayer ameliorate acute lung injury by interfering neutrophil infiltration.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanomedicine for Acute Respiratory Distress Syndrome: From Pathophysiological Mechanisms and Disease Heterogeneity to Precision Therapy.International journal of nanomedicine · 2026Review
- Revolutionizing osteoporosis management: the emerging role of immunotherapeutic and next-generation therapies.Inflammopharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective therapies for acute lung injury (ALI) are still lacking due to poor drug targeting and accumulation, inability to surmount the lung barrier. Nanosystem camouflaged with the membrane of immune cell and responsive lipids offers potential solution. In this study, we developed a nano-immuno-cruise drug delivery system (DDS) using the anti-inflammatory drug naringin (Nar) loaded reactive oxygen species (ROS)-responsive liposomes fused with activated neutrophil membranes (TK-NLP). The TK-NLP showed great targeting ability in both injured 2D epithelial cell model and 3D ALI model based on a 3D printed mimicking lung organ (mLO) with a dynamic environment on chip. Interestingly, TK-NLP could effectively inhibit the formation of platelet-neutrophil aggregates (PNAs), thereby showing great potential for suppressing PNA-mediated inflammatory cascades. Subsequently, in the mouse model of ALI, TK-NLP aggregate specifically at pneumonia sites and respond to the overexpressed ROS with the release of Nar, which reduced neutrophil infiltration and inflammatory factors secretion, protecting the integrity of the lung barrier to ameliorate ALI. Collectively, this nano-immuno-cruise DDS integrating immune camouflage, ROS-responsive controlled drug release, and targeted interference with PNAs formation, offers a novel and promising strategy for precision therapy and barrier repairment for ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.